Related Experiment Video

Updated: Aug 12, 2026

Pentylenetetrazole-Induced Kindling Mouse Model
07:06

Pentylenetetrazole-Induced Kindling Mouse Model

Published on: June 12, 2018

Mutagenic risk in epileptic patients before and after anticonvulsant therapy

S Goyle, A K Maurya, S Kailash

    Epilepsia
    |January 1, 1987
    PubMed

    Insights

    Epilepsy patients exhibit increased mutagenicity, indicated by higher sister chromatid exchange (SCE) rates, regardless of anticonvulsant therapy. Untreated patients, particularly males and those aged 26-50, showed significantly elevated SCE frequencies compared to controls and treated individuals.

    Area of Science:

    • Genetics
    • Clinical Neurology
    • Toxicology

    Background:

    • Anticonvulsant drug therapy is linked to somatic chromosome aberrations in adults.
    • Epilepsy in parents may contribute to congenital malformations in offspring.

    Purpose of the Study:

    • To assess mutagenic susceptibility in male and female epileptic patients using sister chromatid exchange (SCE).
    • To compare SCE frequencies in epileptic patients before and after anticonvulsant therapy against controls.

    Main Methods:

    • Sister chromatid exchange (SCE) analysis, a sensitive mutagenicity indicator.
    • Inclusion of various age groups for both male and female epileptic patients.
    • Comparison between treated, untreated epileptic patients, and a control group.

    Main Results:

    • Significantly higher SCE frequencies were observed in all age groups of treated and untreated epileptic patients compared to controls.
    • Untreated patients aged 26-50 years showed significantly higher SCE frequencies than treated patients (p < 0.01).
    • Untreated male patients exhibited significantly higher SCE frequencies than treated male patients (p < 0.025).

    Conclusions:

    • Epilepsy itself contributes to increased mutagenicity, aligning with previous studies on congenital malformation risks.
    • Elevated SCE frequencies in untreated epileptic patients warrant further investigation to understand their implications.

    More Related Videos

    Electrophoretic Delivery of &#x3B3;-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice07:01

    Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

    Published on: May 16, 2019

    Sampling Cerebrospinal Fluid and Blood from Lateral Tail Vein in Rats During EEG Recordings10:46

    Sampling Cerebrospinal Fluid and Blood from Lateral Tail Vein in Rats During EEG Recordings

    Published on: September 1, 2023

    Related Concept Videos

    Epilepsy and Seizures: Overview01:24

    Epilepsy and Seizures: Overview

    Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
    Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
    Antiepileptic Drugs: Sodium Channel Blockers01:08

    Antiepileptic Drugs: Sodium Channel Blockers

    Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
    Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
    Among the most commonly prescribed antiepileptic drugs are...
    Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

    Antiepileptic Drugs: GABAergic Pathway Potentiators

    γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
    The key GABA pathway potentiators used in epilepsy management are as follows.
    Benzodiazepines are a well-known class of drugs used for their...
    Antiepileptic Drugs: Glutamate Antagonists01:14

    Antiepileptic Drugs: Glutamate Antagonists

    Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
    Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

    Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

    Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
    SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
    Antiepileptic Drugs: Potassium Channel Activators01:20

    Antiepileptic Drugs: Potassium Channel Activators

    Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
    Ezogabine has gained approval as an adjunctive treatment...